These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Special considerations in the management of cytomegalovirus infection in pediatric solid organ transplant recipients].
    Author: Rumbao J, Frauca E.
    Journal: Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 6():70-3. PubMed ID: 22541928.
    Abstract:
    In pediatric patients, the main risk factor for the development of post-transplantation cytomegalovirus (CMV) is the absence of specific immunity to the virus in the pretransplantation period. CMV infection has become less of a problem in pediatric solid organ transplant (SOT) recipients mainly due to the availability of sensitive diagnostic techniques, the development of prevention strategies, and the possibility of starting effective antiviral treatments. Both polymerase chain reaction (PCR) techniques and pp65 antigenemia have proved to be effective in the diagnosis and monitoring of children with CMV infection. However, in some types of transplantation, such as lung transplantation, CMV infection continues to be an important risk factor for mortality or retransplantation in D+/R(-1) patients. Prophylaxis with ganciclovir followed by valganciclovir for between 3 and 6 months is recommended over preemptive therapy. In the treatment of CMV disease, the use of ganciclovir is recommended until a negative weekly result of PCR or pp65 antigenemia is obtained. The total duration of treatment, both in viral syndrome and organ disease, is the same as in adults. Treatment can be completed by substituting intravenous ganciclovir for oral treatment in older children and adolescents.
    [Abstract] [Full Text] [Related] [New Search]